Baroreflex Activation Therapy in Patients with Heart Failure with Reduced Ejection Fraction: BeAT-HF Study Results
Zile MR, Lindenfeld J, Weaver FA, Zannad F, Galle E, Rogers T, Abraham WT
J Am Coll Cardiol. 2020 Jul, 76 (1) 1-13.
The Need to Innovate and Accelerate Clinical Trial Performance: BeAT the Clock
Januzzi JL, Ibrahim NE
J Am Coll Cardiol. 2020 Jul (1) 14-16.
Symptomatic Endpoint Responder Rates to BAROSTIM THERAPY
Abraham WT, Lindenfeld J, Weaver FA, Zannad F, Zile MR, Galle E, Schafer J, Bahu MM
2020 ESC; August 29, 2020 Poster
Quality of Life Response to BAROSTIM THERAPY
Zannad F, Abraham WT, Lindenfeld J, Weaver FA, Galle E, Rogers T, Zile MR
2020 ESC; August 29, 2020 Poster
Baroreflex Activation Therapy in Patients with Heart Failure and Reduced Ejection Fraction: Responder Rates and Quality of Life Measures Analyzed by Gender
Lindenfeld J, Abraham WT, Weaver FA, Zannad F, Galle E, Rogers T, Bahu MM, Grazette L, Zile MR
LBCT 2020 ESC-HF; June 19, 2020 Presentation
Impact of Left Ventricular Ejection Fraction and Atrial Fibrillation on Baroreflex Activation Therapy
Zile MR, Abraham WT, Weaver FA, Zannad F, Galle E, Rogers T, Grazette L, Lindenfeld J
2020 ESC-HF; June 19, 2020 Presentation
BAROSTIM THERAPY in Patients with Heart Failure with a Reduced Ejection Fraction, Impact in Women
Lindenfeld J, Abraham WT, Weaver FA, Zannad F, Zile MR, Galle E, Rogers T, Grazette L
2020 ESC-HF; June 19, 2020 Poster
Does Neuromodulation Using Baroreflex Activation Therapy (BAT) have Potential Application in HFpEF?
Zile MR
2020 HRS; July 31, 2020 Presentation
Cost-Impact Analysis Of Baroreflex Activation Therapy In Patients With Chronic Heart Failure In The United States
Zile MR, Schneider J, Davies S, Galle E, Stojanovic I, Bisognano J
2020 HRS; May 7, 2020 Poster
Symptomatic Responder Rates To Barostim Therapy
Abraham WT, Lindenfeld J, Weaver FA, Zannad F, Zile MR, Galle E, Schafer J, Bahu MM
2020 HRS; May 7, 2020 Presentation
Are Intermediate Endpoints Associated With Serious Adverse Cardiovascular Events: Preliminary Results From The BeAT-HF Trial
Zile MR, Abraham WT, Lindenfeld J, Weaver FA, Zannad F, Rogers T, Awad KA
2020 HRS; May 7, 2020 Presentation
Response To Barostim Therapy By Atrial Fibrillation Status
Zile MR, Lindenfeld J, Abraham WT, Weaver FA, Zannad F, Galle E, Rogers T, Swarup V
2020 HRS; May 7, 2020 Presentation
Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction
Zile MR, Lindenfeld J, Weaver FA, Zannad F, Galle E, Rogers T, Abraham WT
LBCT: 2019 HRS; May 9, 2019 Presentation
Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction
Lindenfeld J, Abraham WT, Weaver FA, Zannad F, Galle E, Rogers T, Zile MR
ESC-HF; May 27, 2019 Presentation
Baroreflex Activation Therapy for the Treatment of Heart Failure with a Reduced Ejection Fraction
Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Müller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC
JACC Heart Fail. 2015;3(6):487-496.
Baroreflex Activation Therapy for the Treatment of Heart Failure with a Reduced Ejection Fraction: Safety and Efficacy in Patients with and without Cardiac Resynchronization Therapy
Zile MR, Abraham WT, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Müller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC
Eur J Heart Fail. 2015;17(10):1066-1074.
Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure with Reduced Ejection Fraction
Weaver FA, Abraham WT, Little WC, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Madershahian N, Müller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Zile MR
Semin Thorac Cardiovasc Surg. 2016;28(2):320-328.
Baroreflex Activation Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction in Patients with and without Coronary Artery Disease
Halbach M, Abraham WT, Butter C, Ducharme A, Klug D, Little WC, Reuter H, Schafer JE, Senni M, Swarup V, Wachter R, Weaver FA, Wilks SJ, Zile MR, Müller-Ehmsen J
Int J Cardiol. 2018;266:187-192.
Carotid Baroreceptor Stimulation, Sympathetic Activity, Baroreflex Function, and Blood Pressure in Hypertensive Patients
Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FC, Haller H, Pichlmaier AM, Luft FC, Jordan J
Hypertension. 2010;55(3):619-626.
Effects of Chronic Baroreceptor Stimulation on the Autonomic Cardiovascular Regulation in Patients with Drug-Resistant Arterial Hypertension
Wustmann K, Kucera JP, Scheffers I, Mohaupt M, Kroon AA, de Leeuw PW, Schmidli J, Allemann Y, Delacrétaz E
Hypertension. 2009;54(3):530-536.
Baroreflex activation therapy: Indication and evidence in resistant hypertension and heart failure
Wallbach M, Koziolek MJ, Wachter R
Internist (Berl). 2018;59(10):1011-1020.